Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
AssigneesThe Regents of the University of Colorado, a body corporate, Konkuk University Industry Cooperation Foundation
InventorsSoohyun Kim, Charles A. Dinarello
Life of this patent
Estimating the term…
Abstract
Embodiments herein report compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.
Claims20
A nucleic acid construct encoding a fusion polypeptide represented by SEQ ID NO:
- 49, SEQ ID NO:
- 56, SEQ ID NO:
- 57, or SEQ ID NO:
- 58.
A nucleic acid construct encoding the fusion polypeptide represented by SEQ ID NO:
- 49.
A composition comprising a fusion polypeptide represented by SEQ ID NO:
- 49, SEQ ID NO:
- 56, SEQ ID NO:
- 57 or SEQ ID NO:
- 58 and a pharmaceutically acceptable carrier.
An isolated preparation of inclusion bodies comprising a fusion polypeptide represented by SEQ ID NO:
- 49, SEQ ID NO:
- 56, SEQ ID NO:
- 57 or SEQ ID NO:
- 58.
A nucleic acid construct encoding a fusion polypeptide represented by SEQ ID NO:56.
A nucleic acid construct encoding the fusion polypeptide represented by SEQ ID NO:
- 57.
A nucleic acid construct encoding a fusion polypeptide represented by SEQ ID NO:
- 58.
Dependencies are inferred from the claim text.